Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy
NCT07461441Phase 3Recruiting
- Sponsor
- Yeungnam University College of Medicine
- Start
- Mar 2026
- Primary completion
- Nov 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of faricimab in polypoidal choroidal vasculopathy (PCV), age-related macular degeneration (AMD), sponsored by Yeungnam University College of Medicine. Started Mar 2026; status: recruiting.
02
Drugs
faricimab
03
Conditions
polypoidal choroidal vasculopathy (PCV)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT07461441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07461441.